Drugmaker AstraZeneca said on Tuesday that its asthma drug Fasenra failed to meet one of two main goals of a late-stage study assessing the treatment’s benefits in a chronic allergic condition that causes difficulty in swallowing.
https://www.pharmalive.com/wp-content/uploads/2021/12/U.S.-FDA-approves-AstraZeneca-Amgen-drug-for-severe-asthma-Reuters-12-17-21.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-10-25 03:22:462022-10-25 09:41:01AstraZeneca drug fails one main goal in study of chronic immune disease
